Regulatory News Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC May 08, 2026Vol.52 No.18By Jacquelyn Cobb
Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel May 08, 2026Vol.52 No.18By Paul Goldberg
Cancer Policy Katherine Szarama steps in as CBER acting director, replacing Prasad May 08, 2026Vol.52 No.18By Claire Marie Porter
Funding Opportunities FDA’s OCE announces funding opportunity in ultra-rare cancers May 08, 2026Vol.52 No.18
Drugs & Targets FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib May 08, 2026Vol.52 No.18By Claire Marie Porter
Drugs & Targets FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease May 08, 2026Vol.52 No.18
Podcast Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time May 06, 2026
Regulatory News FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients“Patients are owed another review.” May 01, 2026Vol.52 No.17By Sara Willa Ernst
Drugs & Targets ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib May 01, 2026Vol.52 No.17By Jacquelyn Cobb
